A meta-analysis of double-blind, placebo-controlled trials lasting 3 to 12 months in mild cognitive impairment and mild Alzheimer's disease found a small advantage for acetyl-L-carnitine over placebo on clinical and psychometric measures.
emerging — human data exists, and it is thin or contested
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Summary
A meta-analysis of double-blind, placebo-controlled trials lasting 3 to 12 months in mild cognitive impairment and mild Alzheimer's disease found a small advantage for acetyl-L-carnitine over placebo on clinical and psychometric measures. · pmid:12598816
In a 24-week randomized trial in 409 women receiving taxane chemotherapy for breast cancer, acetyl-L-carnitine did not prevent neuropathy at 12 weeks and worsened it by 24 weeks compared with placebo. · pmid:23733756
Proportion of the 2 claims about Acetyl-L-Carnitine (ALCAR) standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Acetyl-L-Carnitine (ALCAR) yet.
Dose evidence, rung by rung
No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.
Approved-label dose· a resolved regulatory document names a labelled dose
nothing resolved on this rung
Studied human doses· resolved human studies at the established tier
nothing resolved on this rung
Observational evidence· resolved human data at the emerging tier: thin, or contested
Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. · pmid 12598816 · 2003
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. · pmid 23733756 · 2013
Community-reported protocols· protocol propositions from distinct members, counted once per human
nothing resolved on this rung
Preclinical evidence· resolved animal, cell or mechanistic work
nothing resolved on this rung
2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.